前立腺肥大症に対するGestanon(allylestrenol)の臨床効果

Abstract

Allylestreno1 (Gestanon®), one of popularly used gestagens to prevent abortion, is said to reduce the prostate weight of adult rats showing no androgenic, anabolic or estrogenic effects. These effects fill up the conditions as a remedy of benign prostatic hypertrophy in human.Fourty-five mg allylestrenol was administered daily on 20 cases of the early benign prostatic hypertrophy for 3 months as a pilot study. Effects on subjective symptoms (dysuria and nocturia) and objective findings (uroflowmetry and size of the prostate) were followed up. The former improved in 60% of the cases whereas the latter in 50% of them. Both of them improved in 5 cases (25%), either one of them improved in 12 cases (60%), and neither one of them improved in 3 cases (15%). Totally 85% of the cases were relieved from subjective symptoms and/or objective findings. This result was thought to be rather excellent as a conservative treatment of benign prostatic hypertrophy. Follow-up studies are expected to be done.